Early Detection of β-Cell Decline Using Home Dried Blood Spot C-Peptide Levels in New-Onset Type 1 Diabetes
Diabetes Care · 2025
DOI: 10.2337/dc25-0214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, 2025. Verfasst von A Emile J Hendriks und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, University of Cambridge, Cambridge, U.K. Hauptthemen laut MEDLINE: C-Peptide, Diabetes Mellitus, Type 1, Insulin-Secreting Cells, Dried Blood Spot Testing. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Innovative Medicines Initiative.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE There is a need for early detection of β-cell decline in people with newly diagnosed (ND) type 1 diabetes. The gold standard mixed-meal tolerance test (MMTT) is an invasive and time-consuming procedure that requires participants to travel to clinical sites. We assessed the feasibility of measuring dried blood spot (DBS) C-peptide levels collected at home as an alternative to the MMTT to detect early β-cell decline. RESEARCH DESIGN AND METHODS Individuals with ND type 1 diabetes were recruited within 6 weeks of diagnosis as part of the INNODIA cohort. They collected finger-prick DBS C-peptide data at home, both while fasting and 60 min after a liquid meal. At 12 months, an MMTT was conducted to measure the area under the curve (AUC) of venous C-peptide. RESULTS Data of 292 people were analyzed (mean age 12.7 years; range 1.2–43.8 years). The median number of DBS card pairs per participant was 6.5 (interquartile range = 2, 9) over 12 months. The slopes of stimulated DBS C-peptide levels in the first 6 months significantly predicted venous MMTT AUC C-peptide and peak C-peptide levels at 12 months (P < 0.01). The models were adjusted for simultaneous glucose levels, age, and baseline fasting C-peptide level. However, the 6-month fasting DBS C-peptide slope did not predict 12-month MMTT AUC C-peptide. CONCLUSIONS Home DBS C-peptide assessment is a feasible method to monitor β-cell function in ND type 1 diabetes. The early prognostic utility of stimulated DBS C-peptide highlights its potential for optimizing trial design. However, further validation is needed to confirm its reliability and broader applicability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics, University of Cambridge, Cambridge, U.K.
- Department of Paediatric Diabetes and Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, U.K.
- Institute of Metabolic Science and Department of Medicine, University of Cambridge, Cambridge, U.K.
- National Institute for Health and Care Research Cambridge Biomedical Research Centre, Core Biochemistry Assay Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, U.K.
- Department of Chronic and Metabolic Diseases, KU Leuven, Leuven, Belgium.
- Department of Endocrinology, UZ Gasthuisberg, Leuven, Belgium.
ORCID-Profile: A Emile J Hendriks, M Loredana Marcovecchio, Chantal Mathieu
Förderung
- Innovative Medicines Initiative
Zitieren
APA
Hendriks, A. E. J., Marcovecchio, M. L., Evans, M. L., Barker, P., Burling, K., Overbergh, L., Mathieu, C., & INNODIA Consortium (2025). Early Detection of β-Cell Decline Using Home Dried Blood Spot C-Peptide Levels in New-Onset Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/dc25-0214
Vancouver
Hendriks AEJ, Marcovecchio ML, Evans ML, Barker P, Burling K, Overbergh L, et al. Early Detection of β-Cell Decline Using Home Dried Blood Spot C-Peptide Levels in New-Onset Type 1 Diabetes. Diabetes Care. 2025. doi:10.2337/dc25-0214
BibTeX
@article{Hendriks2025,
author = {Hendriks, A Emile J and Marcovecchio, M Loredana and Evans, Mark L and Barker, Peter and Burling, Keith and Overbergh, Lut and Mathieu, Chantal and INNODIA Consortium, INNODIA Consortium},
title = {Early Detection of β-Cell Decline Using Home Dried Blood Spot C-Peptide Levels in New-Onset Type 1 Diabetes},
journal = {Diabetes Care},
year = {2025},
doi = {10.2337/dc25-0214}
}
EUVIMED